Skip to main content

PerkinElmer Grants GenMark License to Microfluidics Patent Portfolio

NEW YORK (GenomeWeb News) – GenMark Diagnostics today said it has been granted a non-exclusive license to PerkinElmer's microfluidics patent portfolio.

Financial and other terms of the deal were not disclosed.

GenMark President and CEO Hany Massarany said in a statement, "Completing this agreement strengthens GenMark's patent portfolio and provides us with maximum flexibility as we expand our menu of high-value multiplex molecular tests."

PerkinElmer fortified its microfluidics portfolio with the $600 million acquisition of Caliper Life Sciences in November.

"The use of microfluidics for multiplexed molecular testing is a key enabling platform for personalized health research," Kevin Hrusovsky, president of Life Sciences and Technology for PerkinElmer, said. "We continue to leverage our expansive microfluidics portfolio, through non-exclusive licensing such as the one with GenMark, to extend our market reach and create revenue opportunities in applications and markets that complement our direct channel product offerings."

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.